GI Insights

Strong communication is a critical component in improving health outcomes for patients with IBS. What do we need to know to help our patients feel heard and valued? Dr. Peter Buch is joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to discuss how to effectively communicate with our patients.

Patients suffering from disorders of the gut-brain interaction are often subjected to stigma. But what can we do to help challenge these stigmas? Here today is Dr. Peter Buch who will be joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to talk about the impact of stigma in DGBI.

The COVID-19 pandemic has demonstrated the effectiveness of telemedicine, but will this approach still be utilized after the pandemic ends? Dr. Peter Buch is joined by Dr. Andres Nieto, Assistant Professor at Frank H. Netter MD School of Medicine, to discuss the role of telemedicine and its future

Dyspepsia affects a large number of Americans. But what exactly is dyspepsia? And how can we distinguish dyspepsia from other diseases? Joining Dr. Peter Buch to answer those and other questions is Dr. Scott Gabbard, who’s the section head of the Neurogastroenterology and Motility Center at the Cleveland Clinic.

Millions of colonoscopies are performed each year in the United States, but which indicators should we be using to measure the quality of these procedures? Dr. Peter Buch is joined by Dr. Douglas Rex, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, to discuss the importance of these indicators.

The world of healthcare continues to drastically change over the years. But what do you need to know about the variety of employment models available for gastroenterologists today? Dr. Peter Buch is joined by Dr. John Allen, Clinical Professor of Medicine at the University of Michigan School of Medicine, to discuss recent changes in practice models.

Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patient with IBD. Would you make the same decisions?

New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi as they explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient.

Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.

The management of motility disorders like achalasia and gastroparesis can be very complex for both patients and clinicians alike. Fortunately, there have been several advancements in the evaluation and treatment of these disorders. Joining Dr. Peter Buch to walk us through what those developments are and how they can help improve our patients’ quality of life is Dr. Nicole Hanley-Williams, who specializes in motility and functional disorders at Beth Israel Lahey Health.